Bridgepoint-backed Diaverum plans IPO in November – reports

Eliza Punshi
30 October 2020

Tweet
Facebook
LinkedIn
Google plus
Send to

Bridgepoint-backed Diaverum, a Sweden-based renal care provider, is preparing to launch an initial public offering in November, according to press reports.

The transaction could value the company at more than €2bn, Reuters reported.

The report said that JP Morgan, Carnegie and SEB are advising Bridgepoint on the potential listing, which is due to launch before the end of 2020 unless the results of the US elections affect market conditions.

Diaverum was due to list in June at a value of SEK 22-23bn (€2.1-2.2bn), and BDC had appointed Moelis & Company to advise on the potential sale, sister publication Mergermarket previously reported.

The GP in 2007 acquired Diaverum, then known as Gambro Healthcare, from EQT and Investor AB for SEK 6.1bn (€586m).

Founded in 1991 and headquartered in Stockholm, Diaverum provides renal care services ranging from preventive care to dialysis and transplantation. It operates more than 400 clinics in 22 countries.

Bridgepoint declined to comment.